NEW YORK, August 21, 2026, 16:35 EDT
- SELLAS ended the session at $15.46, gaining 15.37%, with trading volume at 1.74 times its average.
- The company’s cash holdings account for just 4.4% of its $3.12 billion market capitalization.
- Investors are anticipating the event-driven final analysis results of the Phase 3 REGAL trial.
SELLAS Life Sciences Group, Inc. NASDAQ:SLS climbed 15.37% on Friday, ending the session at $15.46 — just 2.6% shy of its 12-month peak. The surge lifted the market capitalization of the clinical-stage biotech firm to $3.12 billion.
This valuation reflects $2.98 billion in equity above the disclosed cash position. As of June 30, SELLAS reported holding $138.3 million in cash. That amount accounts for only 4.4% of the market capitalization as of Friday.
The remainder comes from pipeline value. The majority depends on two acute myeloid leukemia programs. One is nearing a pivotal Phase 3 readout. The second is expected to deliver Phase 2 results this year.
| Friday market measure | Level | Move |
|---|---|---|
| SELLAS | $15.46 | up 15.37% |
| Nasdaq Composite | 26,180.46 | gained 0.43% |
| S&P 500 | 7,674.37 | rose 0.43% |
| SELLAS volume | 15.06 million | 1.74 times its three-month average |
| SELLAS 52-week return | — | up 601.57% |
Trading volume on Friday stood at 15.06 million shares, marking a 74% increase over the three-month average. The rise outperformed the Nasdaq by 14.94 percentage points.
A valuation analysis released on Friday described the shares as overextended following their prolonged run-up. Despite the caution, the stock continued to climb. The trading activity indicates that investors may be placing greater confidence in the likelihood of clinical success.
The balance sheet eases immediate financing concerns, though clinical risks remain. The second-quarter net loss expanded to $9.6 million from $6.6 million. Research expenses increased by 62% to $6.3 million.
| Value and pipeline measure | Verified figure | Investor interpretation |
|---|---|---|
| Market capitalization | $3.12 billion | Closed markets on Friday |
| Cash and equivalents | $138.3 million | Represents 4.4% of market capitalization |
| Market value beyond cash | $2.98 billion | Majority tied to pipeline assets |
| Q2 net loss | $9.6 million | 45% higher versus a year ago |
| Shares outstanding | 201.9 million | 31.9% rise from previous year-end |
| SLS009 enrollment | 28 of 80 patients | Topline data expected in Q4 2026 |
The cash infusion resulted in dilution. The number of outstanding shares climbed to 201.9 million from 153.1 million at the end of the year. That 31.9% rise reduced the proportion of ownership for existing shareholders.
The main driver is REGAL, a Phase 3 survival trial enrolling 126 patients. The study evaluates galinpepimut-S as maintenance treatment following a second remission in AML. The final review starts once the 80th death is recorded.
The study reported 78 events as of May 11, with SELLAS still blinded to which treatment patients received. Fewer events over time could indicate improved overall survival in both groups. However, this data does not indicate which arm saw greater benefit.
Chief Executive Angelos Stergiou stated that SELLAS is “approaching the pre-specified 80th event.” Afterward, the database will be locked and a blinded review conducted prior to unblinding. The precise date for results has not been disclosed.
The second programme provides an alternative path. SLS009 had enrolled 28 out of a targeted 80 first-line AML patients as of August 10. Topline results are still expected in the fourth quarter.
In the past week, analysts increased their price targets. Alliance Global highlighted SLS009’s apparent advantage among CDK9 inhibitors. The firm’s $35 target stands 126% higher than Friday’s closing price.
| Analyst | Firm | Recommendation | Target | Upside from $15.46 | Date |
|---|---|---|---|---|---|
| James Molloy | Alliance Global | Buy | $35 | 126.4% | Aug. 17, 2026 |
| Jason McCarthy | Maxim Group | Buy | $30 | 94.0% | Aug. 13, 2026 |
| S&P Global poll | Two analysts | Buy consensus | $32.50 average | 110.2% | Aug. 17, 2026 |
Both arguments gained support over the past week. SELLAS disclosed a robust cash position and analysts raised their targets. However, Friday’s closing price reflected a level of optimism beyond what the balance sheet justifies.
Investors are advised to look out for the 80th event announcement next week, marking the onset of REGAL’s final analysis process. Any changes to the schedule may impact a stock that is currently trading close to its yearly peak.
Risks: REGAL could miss its survival endpoint, even if pooled survival is extended. SLS009 has not received approval, and dilution or increased R&D expenses may reoccur.
Related articles: NASDAQ:SLS
![Australia Stock Market Today 08.22.2026 [UPDATE: 08.22.2026 08:37 AEST] [Weekly Recap and Week Ahead: Healthcare Leads, CPI Looms]](https://ts2.tech/wp-content/uploads/2026/08/AU-market-dashboard-2026-08-22-0837-480x384.jpg "Australia Stock Market Today 08.22.2026 [UPDATE: 08.22.2026 08:37 AEST] [Weekly Recap and Week Ahead: Healthcare Leads, CPI Looms]")
